THOUSAND OAKS (dpa-AFX) - The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Eyebiotech, a privately held ophthalmology-focused biotechnology company, announced they have entered into a definitive agreement under which Merck,
Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, Wednesday announced that it has received Fast Track Designation from the U.S. Food and Drug Administration for combination therapy of AFM24 with Atezolizumab for EGFR Wild-Type non-small cell lung cancer or NSCLC.
WASHINGTON (dpa-AFX) - Pulmatrix (PULM) said it has entered into a cross license with MannKind (MNKD) pursuant to which MannKind will grant Pulmatrix a royalty free, exclusive license to use MannKind's
TScan Therapeutics (TCRX) announced the FDA has granted Regenerative Medicine Advanced Therapy designation to TSC-100 and TSC-101, the two lead TCR-T therapy candidates for the treatment of heme malignancies.